HomeAXGN • NASDAQ
add
AxoGen, Inc Common Stock
Previous close
$13.10
Day range
$12.99 - $13.40
Year range
$5.56 - $15.76
Market cap
587.07M USD
Avg Volume
423.42K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Revenue | 48.64M | 17.86% |
Operating expense | 36.75M | 2.87% |
Net income | -1.86M | 54.56% |
Net profit margin | -3.82 | 61.45% |
Earnings per share | 0.07 | 600.00% |
EBITDA | 1.40M | 150.05% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 24.53M | -24.73% |
Total assets | 191.98M | -1.36% |
Total liabilities | 92.58M | -4.38% |
Total equity | 99.41M | — |
Shares outstanding | 44.01M | — |
Price to book | 5.80 | — |
Return on assets | -0.41% | — |
Return on capital | -0.47% | — |
Cash Flow
Net change in cash
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Net income | -1.86M | 54.56% |
Cash from operations | 3.90M | 139.91% |
Cash from investing | -5.00M | -183.42% |
Cash from financing | 572.00K | 11,340.00% |
Net change in cash | -527.00K | -106.91% |
Free cash flow | 3.60M | 424.35% |
About
Axogen is a developer of surgical solutions, including human tissue grafts, based in Alachua, Florida. Axogen products are designed to remedy peripheral nerve damage. In 2013 the company raised $18 million in its initial public offering. Axogen uses a cell graft technology AVANCE to mimic a human nerve. The company also creates nerve connectors and soft tissue membranes. The company reports sensory and movement recovery in 87 percent of patients with peripheral nerve injuries. Axogen is part of the Sid Martin Biotechnology Incubator.
As of 2019, Axogen was the only commercially available allograft approved by the Food and Drug Administration for clinical use. Wikipedia
Founded
2002
Headquarters
Website
Employees
427
